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Background: It has frequently been demonstrated that experimental lowering of serotonin (5-HT) neurotransmission by acute
tryptophan depletion (ATD) induces a transient depressed mood in 50–60% of patients treated with a selective serotonin
reuptake inhibitor (SSRI) who are in remission from depression. In unmedicated depressed patients, ATD has no immediate
effect on symptoms. The effects in currently depressed medicated patients have not been investigated.
Methods: Fourteen currently depressed patients (seven patients treated with a selective serotonin–noradrenalin reuptake
inhibitor (SSNRI); seven other treatment, non-SSNRI) received ATD in a double-blind, crossover design. Different strengths of
the ATD mixture (aimed at 50% and 90% reduction of tryptophan) were used on separate days. Psychiatric symptoms were
assessed at both sessions prior to, at +6.5 h, and at +24 h after ATD.
Results: The ATD mixtures induced the expected reductions of plasma tryptophan levels. Full but not partial depletion
improved mood and other psychiatric symptoms at +24 h in patients who received SSNRI treatment, as indicated by clinical
ratings and self-report. Subjective sleep quality also improved.
Conclusions: The effects of ATD on psychiatric symptoms in currently depressed patients are remarkably different from the
results in recently remitted SSRI-treated patients. ATD in currently depressed patients treated with serotonergic antidepressants
possibly provides important information about the mechanism of action of SSRIs.
D 2005 Elsevier B.V. All rights reserved.
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Acute tryptophan depletion (ATD) induces a
transient depressed mood in some patients who are
in remission from depression (Van der Does, 2001;
Booij et al., 2002, 2003). In recently remitted
patients, the probability of ATD response is highest
in patients treated with a selective serotonin
reuptake inhibitor (SSRI) (Delgado et al., 1990,
1999). Three studies investigated ATD in currently
depressed patients, and all reported no mood
effects on the depletion day (Delgado et al.,
1994; Price et al., 1997, 1998). However, Delgado
et al. (1994) reported a worsening of mood on the
next day in one third of the patients, whereas one
fourth showed a clinical improvement, and the
direction of change was predictive of treatment
responsiveness. This bimodal delayed mood effect
was not found in the two other studies (Price et
al., 1997, 1998); however these included a 5-HT
challenge at the point of maximal depletion. This
indicates that ATD in currently depressed patients
may cause a compensatory upregulation of 5-HT
receptors.
Considering its potential clinical relevance, a
replication of the study by Delgado et al. (1994) is
warranted. However, because it is very difficult to
recruit medication-free depressed patients in secon-
dary settings, we explored the effects of ATD in
currently depressed patients treated with medica-
tions acting on the 5-HT system. There is a reason
to believe that the effects of ATD in medicated
symptomatic patients may be different from the
effects in unmedicated patients and patients in
remission. The 5-HT1A antagonist pindolol has
been found to accelerate the therapeutic effects of
antidepressants that affect the 5-HT system, espe-
cially in the first 2 weeks of treatment (Artigas et
al., 2001; Ballesteros and Callado, 2004). Depletion
of 5-HT decreases 5-HT synthesis (Nishizawa et al.,
1997) and may increase postsynaptic activity in
unmedicated patients, as shown by the response to
a 5-HT challenge after ATD (Price et al., 1997,
1998). ATD in currently SSRI-treated patients may
accelerate the desensitization process, and conse-
quently accelerate therapeutic response.
In conclusion, we hypothesized that ATD would
improve symptoms in currently depressed patientstreated with serotonergic antidepressants, and would
have no effect in depressed patients who receive other
treatments.2. Materials and methods
2.1. Participants
Eligible patients were outpatients of a mood
disorders clinic. Inclusion criteria were: age between
18 and 65 years, met DSM-IV criteria for current
depression, Hamilton Depression Rating Scale
(HRSD, 17 items) (Hamilton, 1960) N15, or
Montgomery Asberg Depression Rating Scale
(MADRS) (Montgomery and Asberg, 1979) N17.
Exclusion criteria were: substance abuse within the
past 3 months, psychosis (lifetime), physical illness,
lactation, and pregnancy. Clinical background varia-
bles and diagnoses were assessed with the Structured
Clinical Interview for DSM-IV (SCID-I) (First et al.,
1995).
2.2. Amino acids
At each depletion session, patients received in
randomized order either 100 g or 25 g of ATD
mixture (cf. Booij et al., 2005). The composition of
the 100 g mixture was similar as in Delgado et al.
(1990). The 25 g mixture consisted of the same
amino acids (AAs) but in one quarter amount (Krahn
et al., 1996).
2.3. Instruments
Symptoms were assessed using the Comprehen-
sive Psychopathological Rating Scale (CPRS)
(Goekoop et al., 1992). The CPRS is a 68-item
interview/observation scale with items ranging
from 0 to 6, including the MADRS (Montgomery
and Asberg, 1979) and the Brief Anxiety Scale
(BAS) (Tyrer et al., 1984). Factor-analytic research
has revealed that the CPRS consists of six factors
(Goekoop et al., 1992). The 17-item HRSD (Hamil-
ton, 1960) was also administered. Self-report meas-
ures included the Beck Depression Inventory II (BDI-
II) (Beck et al., 1996), the Positive and Negative
Affectivity Scale (PANAS) (Watson et al., 1988), and
Table 2
Clinical and demographic characteristics of the sample (n=14)
SSNRI Non-SSNRI
M/F 2/5 3/4
Age (S.D.) 46.1 (8.7) 43.1 (10.0)
Type of medication Venlafaxine
(n=5)
None (n=4)
Venlafaxine+
lithium (n=1)
Lithium (n=1)
Mirtazapine
(n=1)
TCA (n=2)
Duration of antidepressant
treatment until full ATD
session (S.D.)
37.6 (39.1)
daysa
Lithium: 3 years
TCA: 7 days and
20 days
Diagnosis 6 4
Major depressive
disorder
0 1
Bipolar disorder, type I,
last episode depressive
1 2
Bipolar disorder, type II,
last episode depressive
Other diagnosis 2 2
Dysthymia 3 0
Anxiety disorder 2 0
Bulimia nervosa/binge
eating disorder
Single/recurrent episodes 2/5 3/4
Duration of current episode
(months) FS.D.
9.6 (5.7)
[range 1–18]
22.6 (21.7)
[range 1–60]b
MADRS at intake (S.E.) 26.4 (2.9)
[range 18–34]
23.4 (2.4)
[range 18–41]
17-Item HRSD at intake
(S.E.)
18.6 (1.1)
[range 8–24]
17.1 (2.0)
[range 15–22]
BDI-II at intake (S.E.) 34.9 (3.1)
[range 13–45]
27.6 (4.3)
[range 23–46]
Full depletion first 3 3
Table 1
Scheme of the ATD procedure
Time Assessment
F1 week
before ATD
Informed consent, intake session including
symptom questionnaires and SCID
24 h Low Trp diet (160 mg/day) until next day
1 h Symptom assessments, blood sample
0 h ATD mixture (25 g or 100 g)
+6 h Blood sample
+6.5 h Symptom assessments
+7.5 h End of session and dietary restrictions
+24 h Symptom assessments, blood sample
This procedure was repeated about 1 week later; those who had
received the 100% mixture received the 25% mixture and vice
versa. SCID=Structured Clinical Interview for DSM-IV; ATD=acute
tryptophan depletion.
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ranging from 0 (absent) to 4 (very intense). All
questions referred to the symptoms at the moment of
assessment. Clinical ratings were performed by a rater
who was blind to the sequence of the mixtures and to
the study hypothesis.
Venous blood was obtained to determine total
plasma tryptophan (Trp) and the ratio of Trp/large
neutral amino acids (LNAA).
2.4. Procedure
The procedure was identical as in Booij et al. (in
press), and is summarized in Table 1.
2.5. Statistical analyses
The outcome variables were analyzed by general
linear models (GLM) for repeated measures, using
intervention (100 g AA vs. 25 g AA) and time of
assessment (pre vs. post depletion vs. the next day) as
within-subjects factors. Non-parametric tests were
used when necessary.SSNRI=selective serotonin–noradrenalin reuptake inhibitor; TCA=
tricyclic antidepressant; MADRS=Montgomery–Asberg Depression
Rating Scale; HRSD=Hamilton Depression Rating Scale; BDI-
II=Beck Depression Inventory—2nd edition.
a One patient used venlafaxine 75 mg/day for about 100 days
before the full depletion session. Without this patient, the mean
duration (S.D.) is 27.2 (10.2) days.
b Without the patient with the duration of episode of 60 months,
the mean duration (S.D.) became 16.4 (15.5) days.3. Results
3.1. Patients
Sixteen patients were included. Two SSRI-treated
patients (both full depletion session) dropped out afterthe first session. One patient found the ATD session
too tiring; another patient was unable to schedule the
second session within a reasonable time interval. The
clinical characteristics of the remaining patients
(seven SSNRI, seven other treatments–no SSRIs) are
summarized in Table 2. There were no baseline group
differences.
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Fig. 2. MADRS scores during full depletion for non-SSNRI-treated
patients. Score on the sleep item is not included.
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Full depletion reduced total Trp and the Trp/LNAA
ratio by 85.9% (S.E.=2.8) and 93.3% (S.E.=2.6),
respectively, at +6 h. During partial depletion, the
average reductions were 57.8% (S.E.=3.2) and 57.1%
(S.E.=3.9), respectively. At t(+24 h), Trp and Trp/
LNAA levels were still reduced by 8.7% (S.E.=6.3)
and 26.5% (S.E.=6.2) after full depletion, but were
increased by 14.9% (S.E.=9.0) and 16.8% (S.E.=4.8)
after partial depletion. No between-group differences
were found.
3.3. Symptoms
SSNRI-treated patients reported a relief of symp-
toms at t(+24 h) after full depletion (Figs. 1 and 2;
Table 3). The improvement occurred across a broad
range of affective symptoms. Subjective sleep quality
was notably improved. At t(+6.5 h), the CPRS
subscale dmotivational disintegrationT was slightly
higher; this was due to an increase of the items
delation,T dlabile emotional responses,T doveractivity,T
and/or delated moodT in four patients in this group.
In the depressed patients treated otherwise, none of
the symptom scales was affected at t(+6.5 h) or
t(+24 h).
Nonparametric Wilcoxon tests between t(1 h)
and t(+24 h) for the full depletion condition in the
SSNRI group revealed a similar pattern, but now0
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Fig. 1. MADRS scores during full depletion for SSNRI-treated
patients. Score on the sleep item is not included. (a) 75 mg/day; (b)
150 mg/day; (c) 225 mg/day; (d) 275 mg/day.the HRSD was also significant (Z=2.03; P=0.04)
and a trend was found for BDI total (Z=1.78;
P=0.07).4. Discussion
High-dose ATD improved symptoms in currently
depressed patients treated with the SSNRI venlafax-
ine, whereas no effects were found in depressed
patients receiving other treatments. The finding that
depleting 5-HT relieves depressive symptoms may be
counterintuitive, but is in line with the finding that 5-
HT1A antagonists, like pindolol, accelerate the
therapeutic response when given concomitantly with
SSRIs in the early phase of antidepressant treatment
(Blier, 2003). Acute SSRI administration initially
activates somatodendritic 5-HT1A autoreceptors due
to increased extracellular 5-HT, and, consequently,
reduced 5-HT neuron firing activity. After prolonged
administration, SSRIs desensitize presynaptic inhib-
itory 5-HT1 autoreceptors and downregulate postsy-
naptic 5-HT1A and 5-HT2 receptors, resulting in a
normalization of 5-HT neuron firing activity (Blier
and de Montigny, 1994). As ATD substantially
reduces 5-HT levels in the brain (Nishizawa et al.,
1997), ATD in medicated depressed patients–in whom
autoreceptors may not yet have sufficiently been
desensitized–may prevent the initial decrease in 5-
HT neuron firing activity that usually occurs after
Table 3
Means (S.E.) of the mood questionnaires for the SSNRI-treated group, broken down by condition and time of assessment
Intervention Partial ATD Full ATD Intervention by time
Questionnaire/time t(1 h) t(+6.5 h) t(+24 h) t(1 h) t(+6.5 h) t(+24 h) F(df); P
CPRS
Emotional dysregulation 30.3(3.8) 33.4(3.0) 31.9(5.5) 37.0(5.6) 35.4(6.8) 22.1(4.8)a F(2,12)=5.2; P=0.02
Motivational inhibition 6.4(1.5) 7.3(0.9) 6.3(1.4) 7.1(1.3) 7.6(2.2) 5.4(1.8) F(2,12)=0.4; P=0.65
Motivational disintegration 1.1(0.5) 0.4(0.2) 0.6(0.4) 0.0(0.0) 1.4(0.6)b 0.4(0.3) F(2,12)=4.3; P=0.04
Perceptual disintegration 0.3(0.2) 0.4(0.3) 0.1(0.1) 0.4(0.3) 0.6(0.4) 0.0(0.0) F(2,12)=0.2; P=0.73
Behavioral disintegration 2.0(1.0) 2.7(0.8) 1.7(1.1) 1.6(0.5) 1.9(1.2) 1.9(0.9) F(2,12)=0.4; P=0.69
Autonomic dysregulation 4.1(0.8) 5.9(1.7) 6.9(1.9) 4.4(1.1) 6.1(2.1) 2.6(1.3)a F(2,12)=3.1; P=0.08
MADRS 19.6(3.3) 22.9(2.0) 20.1(3.9) 22.7(3.7) 23.1(4.7) 13.6(4.0)a F(2,12)=4.2; P=0.04
BAS 9.8(1.8) 11.1 (2.5) 13.6(3.0) 11.8(1.8) 11.6(3.1) 6.6(2.1)a F(2,12)=4.0; P=0.05
HRSD 11.4(1.4) 13.6(1.3) 12.3(2.0) 12.9(1.5) 13.1(1.9) 9.6(1.5) F(2,12)=2.1; P=0.17
Sleep items MADRS 1.3(0.8) 2.0(0.6) 3.4(0.7) 0.7(0.4) Z=1.78; P=0.07
Sleep items HRSD 1.8(0.8) 1.6(0.5) 2.3(0.6) 0.6(0.3)a Z=2.04; P=0.04
BDI-II total score 23.8(4.0) 23.0(2.9) 25.2(3.9) 30.3(2.9) 26.0(2.9) 22.8(3.4) F(2,10)=2.7; P=0.11
PANAS
Positive 20.3(2.7) 17.7(1.3) 15.3(1.5) 21.2(2.7) 18.5(3.6) 17.3(1.9) F(2,10)=0.2; P=0.85
Negative 19.5(3.9) 22.7(2.9) 23.5(4.3) 24.5(3.3) 21.0(3.2)b 18.5(2.7)a F(2,10)=5.4; P=0.03
Side effects 36.7(13.0) 36.3(13.0) 38.0(13.0) 47.0(14.7) 36.1(16.5) 28.3(11.9) F(2,10)=1.0; P=0.42
SSNRI=selective serotonin–noradrenalin reuptake inhibitor; CPRS=Comprehensive Psychopathology Rating Scale; MADRS=Montgomery–
Asberg Depression Rating Scale; BAS=Brief Anxiety Scale; HRSD=Hamilton Depression Rating Scale; BDI-II=Beck Depression Inventory—
2nd edition; PANAS=Positive and Negative Affectivity Scale.
a Vs. t(1 h); 0.01bPb0.05.
b Vs. t(1 h); Pb0.01. Data were missing for one patient on the self-report questionnaires.
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activation of postsynaptic 5-HT receptors.
An alternative explanation for the relief in symp-
toms may be that ATD counteracts the side effects of
SSRIs, which may be caused by the acute rise of 5-HT
(Stahl, 1998). However, there was no change on the
list of physical complaints.
The present study has several limitations. Firstly,
we did not systematically assess the duration of
improvement beyond the first 24 h. Also, patients
had been taking antidepressant medication for vary-
ing time periods. The sample was too small to
investigate possible differences between patients who
had not yet responded and patients who may have
been treatment-resistant.
An important point concerns the generalizability of
the present results, if replicable, to other serotonergi-
cally acting medications. Six patients were treated
with venlafaxine and one patient with mirtazapine.
The rationale to include the latter patient in the SSNRI
group was that mirtazapine-treated patients in remis-
sion also respond to ATD (Delgado et al., 2002). A
number of studies have shown that SSNRIs inhibit the
reuptake of both serotonin and norepinephrin (NE)only at high doses (see Thase et al., 2001; Burke,
2004). Moreover, electrophysiological studies have
shown that venlafaxine induces higher transporter
affinity (Beique et al., 1998b), reuptake (Beique et al.,
1998a, 1999), and extracellulair activity (David et al.,
2003) for 5-HT compared to NE. It is expected that
the effects are similar as in SSRI-treated patients.
To conclude, the present study shows that the
response to ATD in currently depressed medicated
patients may provide useful information about the
underlying pharmacological mechanisms of action of
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